Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) fell 18.5% in the pre-market session after the company ...

Clinical research company Fortrea Holdings (NASDAQ:FTRE) missed Wall Street’s revenue expectations in Q4 CY2024, with sales ...

Discover how FTRE's $7.7B backlog, CRO market growth, and focus on high-margin areas ensure long-term growth, efficiency, and ...

Fortrea (NASDAQ:FTRE – Get Free Report) had its price objective lowered by investment analysts at Barclays from $25.00 to $12 ...

Fortrea (NASDAQ:FTRE – Get Free Report) had its target price decreased by analysts at The Goldman Sachs Group from $22.00 to ...

Q4 2024 Earnings Call Transcript March 3, 2025 Fortrea Holdings Inc. misses on earnings expectations. Reported EPS is $0.18 ...

BofA lowered the firm’s price target on Fortrea (FTRE) to $10 from $17 and keeps an Underperform rating on the shares after a Q4 miss and FY25 ...

Project Optimus seeks to transform how doses are selected and optimised in oncology drug development. As this initiative ...

Barclays lowered the firm’s price target on Fortrea (FTRE) to $12 from $25 and keeps an Equal Weight rating on the shares.Discover the Best ...

A Durham company with a slumping stock is implementing changes to its board after reaching a deal with an activist investor.

Fortrea is a global, late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions.